Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Current Deferred Revenue (2019 - 2025)

Silence Therapeutics' Current Deferred Revenue history spans 7 years, with the latest figure at $168000.0 for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 45.1% to $168000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $168000.0, a 45.1% decrease, with the full-year FY2025 number at $168000.0, down 45.1% from a year prior.
  • Current Deferred Revenue hit $168000.0 in Q4 2025 for Silence Therapeutics, down from $301000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for SLN hit a ceiling of $10.4 million in Q4 2022 and a floor of $168000.0 in Q4 2025.
  • Historically, Current Deferred Revenue has averaged $3.0 million across 5 years, with a median of $424500.0 in 2025.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 81.6% in 2022 and later tumbled 95.22% in 2024.
  • Tracing SLN's Current Deferred Revenue over 5 years: stood at $5.7 million in 2021, then skyrocketed by 81.6% to $10.4 million in 2022, then plummeted by 38.39% to $6.4 million in 2023, then crashed by 95.22% to $306000.0 in 2024, then plummeted by 45.1% to $168000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for SLN at $168000.0 in Q4 2025, $301000.0 in Q3 2025, and $457000.0 in Q2 2025.